CLOs on the Move


 
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kariusdx.com
  • 975 Island Drive Suite 101
    Redwood City, CA USA 94065
  • Phone: 866.452.7487

Executives

Name Title Contact Details
Stephen Malaska
Chief Legal Officer Profile

Similar Companies

NewNeural

NewNeural is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

A W Research Laboratories

A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARIS MPI

CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.